Search Results

You are looking at 1 - 10 of 363 items for :

  • "Neutropenia" x
  • Refine by Access: All x
Clear All
Full access

Real-World Impact of Prophylactic Growth Factor Use on Timing of Febrile Neutropenia and Infection After High-Risk Chemotherapy

Douglas W. Blayney, Nicole M. Kuderer, Alice Kate Cummings Joyner, John Jarvis, Dominic Nunag, Jasmine Wells, Lan Huang, Ramon Monhanlal, and Gary H. Lyman

Background Patients with breast cancer treated with myelosuppressive chemotherapy are at an increased risk of developing febrile neutropenia (FN), a medical emergency characterized by the occurrence of fever during a period of significant

Full access

Antibacterial Prophylaxis in Patients with Neutropenia

Brahm H. Segal and Alison G. Freifeld

-induced neutropenia: risks, consequences, and new directions for its management . Cancer 2004 ; 100 : 228 – 237 . 2. Lyman GH Morrison VA Dale DC . Risk of febrile neutropenia among patients with intermediate-grade non-Hodgkin's lymphoma receiving CHOP

Full access

Prevention, Diagnosis, and Treatment of Invasive Fungal Infections in Patients with Cancer and Neutropenia

Thomas A. Cumbo and Brahm H. Segal

Elser C . Early detection of chronic disseminated Candida infection in leukemia patients with febrile neutropenia: value of computer-assisted serial ultrasound documentation . Ann Hematol 1998 ; 77 : 41 - 45 . 10 Bjerke JW Meyers JD

Full access

Early Antibiotic Discontinuation or De-escalation in High-Risk Patients With AML With Febrile Neutropenia and Prolonged Neutropenia

William Alegria, Bernard L. Marini, Kevin Sellery Gregg, Dale Lee Bixby, Anthony Perissinotti, and Jerod Nagel

Background The optimal duration of antibiotic therapy for patients with febrile neutropenia (FN) remains unknown. The Infectious Diseases Society of America recommends broad-spectrum intravenous antibiotic therapy until neutrophil count recovery

Full access

A Patient Risk Model of Chemotherapy-Induced Febrile Neutropenia: Lessons Learned From the ANC Study Group

Gary H. Lyman and Marek S. Poniewierski

Neutropenia and its complications represent the major dose-limiting toxicities associated with systemic cancer chemotherapy and is associated with considerable morbidity, mortality, and cost. 1 Neutropenic events may result in dose reductions or

Full access

BBCIC Research Network Analysis of First-Cycle Prophylactic G-CSF Use in Patients Treated With High–Neutropenia Risk Chemotherapy

Pamala A. Pawloski, Cara L. McDermott, James H. Marshall, Vanita Pindolia, Catherine M. Lockhart, Catherine A. Panozzo, Jeffrey S. Brown, and Bernadette Eichelberger

Background Prophylaxis with the recombinant human granulocyte colony-stimulating factors (G-CSFs) filgrastim and pegfilgrastim prevents chemotherapy-induced neutropenia; reduces febrile neutropenia (FN) risk and infection-related and early

Full access

Real-World Impact of a Decision Support Tool on Colony-Stimulating Factor Use and Chemotherapy-Induced Febrile Neutropenia Among Patients With Breast Cancer

Abiy Agiro, Andrea DeVries, Jennifer Malin, and Michael J. Fisch

Factors recommend febrile neutropenia (FN) prophylaxis using a colony-stimulating factor (CSF) when risk, based on the chemotherapy regimen and patient risk factors, is “high” (>20%). 7 CSF prophylaxis may also be considered based on patient risk factors

Full access

Risk and Timing of Neutropenic Events in Adult Cancer Patients Receiving Chemotherapy: The Results of a Prospective Nationwide Study of Oncology Practice

Jeffrey Crawford, David C. Dale, Nicole M. Kuderer, Eva Culakova, Marek S. Poniewierski, Debra Wolff, and Gary H. Lyman

. Talcott JA Siegel RD Finberg R Goldman L . Risk assessment in cancer patients with fever and neutropenia: a prospective, two-center validation of a prediction rule . J Clin Oncol 1992 ; 148 : 2561 – 2568 . 2. Kuderer NM Dale DC Crawford JC

Full access

Treatment Strategies for Myeloid Growth Factors and Intravenous Iron: When, What, and How?

Jeffrey Crawford and George M. Rodgers

Chemotherapy-induced neutropenia is hazardous for 2 reasons: it produces febrile neutropenia (FN), which may result in life-threatening infections and prolonged hospitalizations, and it can necessitate chemotherapy dose reductions and delays

Full access

Management of Chemotherapy-Induced Neutropenia: Measuring Quality, Cost, and Value

Michaela A. Dinan, Bradford R. Hirsch, and Gary H. Lyman

the future by more sophisticated personalization of care and more selective administration of interventions to those who stand to benefit most. Use Case: Colony-Stimulating Factors for the Prevention of Febrile Neutropenia Febrile neutropenia